Biocon’s 30-person clinical trial. Similar doubts were expressed by many in the medical and scientific fraternities in the days after the Drug Controller General of India granted emergency use authorisation for the drug.But the bar for evidence has not been uniform, or, at the very least, transparent.
In the US, the recommendation by its National Institutes for Health for or against most known drugs is accompanied in its clinical guidelines with the evidence behind each such recommendation.In India, drugs have appeared and disappeared from the protocol, which is published by the Ministry of Health and Family Welfare, with no explanation.